Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Noncanonical JAK1/STAT3 interactions with TGF-β modulate myofibroblast transdifferentiation and fibrosis
Wang, Faping , Wang, Shaohua , Zhang, Chujie , Tian, Xue, Zhou, Yongfang , Xuan, Weixia , Matteson, Eric L. , Luo, Fengming, Tschumperlin, Daniel J. , Vassallo, Robert , Tschumperlin, Daniel J , Vassallo, Robert , Tian, Xue

Mayo Clinic

American Journal of Physiology-Lung Cellular and Molecular Physiology | October 25, 2022 | Volume: 323 | Issue: 6 | Pages: L698-L714

10.1152/ajplung.00428.2021 | PMID 36283961 Get It

Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with limited survival. Janus kinases (JAKs), tyrosine kinases that transduce cytokine-mediated signals, are known to be involved, but their specific roles in lung fibrosis are not well defined. In this study, the interactions between JAK1/signal transducers and activators of transcription (STAT)3 signaling and transforming growth factor-beta (TGF-β)-induced fibroblast responses were investigated using both pharmacological and siRNA approaches in human normal and IPF-derived lung fibroblasts. We found that JAK1 directly interacts with the TGF-β receptor I subunit (TβRI), and silencing JAK1 promotes myofibroblast transdifferentiation. However, the suppression of JAK1 signaling in vitro and in vivo using an inhibitor (upadacitinib) did not alter lung fibroblast activation or fibrosis development. STAT3 was constitutively active in cultured primary lung fibroblasts; this STAT3 activation required JAK1 and repressed myofibroblast transdifferentiation. Loss of phosphorylated STAT3 following transcriptional JAK1 silencing promoted myofibroblast transdifferentiation. In contrast, transcriptional silencing of unphosphorylated STAT3 suppressed TGF-β signaling, decreased SMAD3 activation, and reduced myofibroblast transdifferentiation and ECM production. Taken together, these observations support a role for JAK1/STAT3 as a direct regulator of TGF-β signaling in lung fibroblasts. Modulation of JAK1/STAT3 signaling in lung fibroblasts represents a noncanonical approach to regulating TGF-β-induced fibrosis and suggests the potential for a novel approach to treat pulmonary fibrosis.
Effect of Patient-Reported Preprocedural Physical and Mental Health on 10-Year Mortality After Percutaneous or Surgical Coronary Revascularization
Ono, Masafumi , Serruys, Patrick W. , Garg, Scot , Kawashima, Hideyuki , Gao, Chao , Hara, Hironori , Lunardi, Mattia , O’Leary, Neil , Mack, Michael J. , Holmes, David R. , Morice, Marie‐Claude, Thuijs, Daniel J.F.M. , Mohr, Friedrich W., Davierwala, Piroze , Spertus, John A. , Onuma, Yoshinobu , Investigators, for the SYNTAX Extended Survival, Piek, Jan J , Mack, Michael J , Holmes, David R , Thuijs, Daniel J F M , Spertus, John A , Cohen, David Jonathan , Onuma, Yoshinobu , Serruys, Patrick W , Garg, Scot , Wang, Rutao , Wykrzykowska, Joanna J. , Kappetein, A. Pieter , Noack, Thilo , Investigators, for the SYNTAX Extended Survival

Mayo Clinic

Circulation | October 24, 2022 | Volume: 146 | Issue: 17 | Pages: 1268-1280

10.1161/circulationaha.121.057021 | PMID 35862109 Get It

Background: Clinical and anatomical characteristics are often considered key factors in deciding between percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) in patients with complex coronary artery disease (CAD) such as left-main CAD or 3-vessel disease. However, little is known about the interaction between self-reported preprocedural physical/mental health and clinical outcomes after revascularization. Methods: This subgroup analysis of the SYNTAXES trial (SYNTAX Extended Survival), which is the extended follow-up of the randomized SYNTAX trial (Synergy Between PCI With Taxus and Cardiac Surgery) comparing PCI with CABG in patients with left-main CAD or 3-vessel disease, stratified patients by terciles of Physical (PCS) or Mental Component Summary (MCS) scores derived from the preprocedural 36-Item Short Form Health Survey, with higher PCS and MCS scores representing better physical and mental health, respectively. The primary end point was all-cause death at 10 years. Results: A total of 1656 patients with preprocedural 36-Item Short Form Health Survey data were included in the present study. Both higher PCS and MCS were independently associated with lower 10-year mortality (10-point increase in PCS adjusted hazard ratio, 0.84 [95% CI, 0.73–0.97]; P =0.021; in MCS adjusted hazard ratio, 0.85 [95% CI, 0.76–0.95]; P =0.005). A significant survival benefit with CABG over PCI was observed in the highest PCS (>45.5) and MCS (>52.3) terciles with significant treatment-by-subgroup interactions (PCS P interaction =0.033, MCS P interaction =0.015). In patients with both high PCS (>45.5) and MCS (>52.3), 10-year mortality was significantly higher with PCI compared with CABG (30.5% versus 12.2%; hazard ratio, 2.87 [95% CI, 1.55–5.30]; P =0.001), whereas among those with low PCS (≤45.5) or low MCS (≤52.3), there were no significant differences in 10-year mortality between PCI and CABG, resulting in a significant treatment-by-subgroup interaction ( P interaction =0.002). Conclusions: Among patients with left-main CAD or 3-vessel disease, patient-reported preprocedural physical and mental health status was strongly associated with long-term mortality and modified the relative treatment effects of PCI versus CABG. Patients with the best physical and mental health had better 10-year survival with CABG compared with PCI. Assessment of self-reported physical and mental health is important when selecting the optimal revascularization strategy. Registration: URL: https://www.clinicaltrials.gov ; SYNTAXES Unique identifier: NCT03417050. URL: https://www.clinicaltrials.gov ; SYNTAX Unique identifier: NCT00114972.
Associations between body mass index, weight loss and overall survival in patients with advanced lung cancer
Oswalt, Cameron , Liu, Yingzhou , Pang, Herbert , Wang, Xiaofei , Crawford, Jeffrey , Crawford, Jeffrey , Liu, Yingzhou, Le‐Rademacher, Jennifer

Mayo Clinic

Journal of Cachexia, Sarcopenia and Muscle | October 21, 2022 | Volume: 13 | Issue: 6 | Pages: 2650-2660

10.1002/jcsm.13095 | PMID 36268548 Get It

AbstractBackgroundWeight loss (WL) has been associated with shorter survival in patients with advanced cancer, while obesity has been associated with longer survival. Integrating body mass index (BMI) and WL provides a powerful prognostic tool but has not been well‐studied in lung cancer patients, particularly in the setting of clinical trials.MethodsWe analysed patient data (n = 10 128) from 63 National Cancer Institute sponsored advanced non‐small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) trials. Risk matrices were created using BMI and WL percentage, which were divided into ‘grades’ based on median survival. Relationships between survival, BMI and WL percentage were examined using Kaplan–Meier estimators and Cox proportional hazards (PH) models with restricted cubic splines.ResultsFor NSCLC, a twofold difference was noted in median survival between the BMI > 28 and WL ≤ 5% group (13.5 months) compared with the BMI < 20 and WL > 5% group (6.6 months). These associations were less pronounced in SCLC. Kaplan–Meier curves showed significant survival differences between grades for both NSCLC and SCLC (log‐rank, P < 0.0001). In Stage IV NSCLC, Cox PH analyses with restricted cubic splines demonstrated significant associations between BMI and survival in both WL ≤ 5% (P = 0.0004) and >5% (P = 0.0129) groups, as well as in WL > 5% in Stage III (P = 0.0306). In SCLC, these relationships were more complex.ConclusionsBMI and WL have strong associations with overall survival in patients with advanced lung cancer, with a greater impact seen in NSCLC compared with SCLC. The integration of a BMI/WL grading scale may provide additional prognostic information and should be included in the evaluation of therapeutic interventions in future clinical trials in advanced lung cancer.
A phenotype-based forward genetic screen identifies Dnajb6 as a sick sinus syndrome gene
Ding, Yonghe , Yan, Jianhua , Li, Hongsong , Jiao, Kunli , Yang, Jingchun , Port, Jenna , Wang, Jun , Shi, Yongyong , Li, Yi‐Gang , Bu, Haisong, Clark, Karl J , Ekker, Stephen C , Lin, Xueying , Ding, Yonghe , Lang, Di , Bu, Haisong , Ni, Haibo , Morotti, Stefano , Le, Tai , Clark, Karl J. , Ekker, Stephen C. , Cao, Hung , Zhang, Yuji , Grandi, Eleonora , Li, Zhiqiang , Glukhov, Alexey V. , Xu, Xiaolei

Mayo Clinic

eLife | October 18, 2022 | Volume: 11 | Issue: No issue available | Pages: No page available

10.7554/elife.77327 | PMID 36255053 Get It

Previously we showed the generation of a protein trap library made with the gene-break transposon (GBT) in zebrafish ( Danio rerio ) that could be used to facilitate novel functional genome annotation towards understanding molecular underpinnings of human diseases (Ichino et al, 2020). Here, we report a significant application of this library for discovering essential genes for heart rhythm disorders such as sick sinus syndrome (SSS). SSS is a group of heart rhythm disorders caused by malfunction of the sinus node, the heart’s primary pacemaker. Partially owing to its aging-associated phenotypic manifestation and low expressivity, molecular mechanisms of SSS remain difficult to decipher. From 609 GBT lines screened, we generated a collection of 35 zebrafish insertional cardiac (ZIC) mutants in which each mutant traps a gene with cardiac expression. We further employed electrocardiographic measurements to screen these 35 ZIC lines and identified three GBT mutants with SSS-like phenotypes. More detailed functional studies on one of the arrhythmogenic mutants, GBT411 , in both zebrafish and mouse models unveiled Dnajb6 as a novel SSS causative gene with a unique expression pattern within the subpopulation of sinus node pacemaker cells that partially overlaps with the expression of hyperpolarization activated cyclic nucleotide gated channel 4 (HCN4), supporting heterogeneity of the cardiac pacemaker cells.
Implantable Peripheral Nerve Stimulation for Peripheral Neuropathic Pain: A Systematic Review of Prospective Studies
Char, Steven , Jin, Max Y. , Francio, Vinicius Tieppo , Hussain, Nasir , Wang, Eric J. , Morsi, Mahmoud , Orhurhu, Vwaire , Fink, Adam, D’Souza, Ryan S. , D'Souza, Ryan S , Tieppo Francio, Vinicius , Wang, Eric , Prokop, Larry J. , Fink, Adam

Mayo Clinic

Biomedicines | October 17, 2022 | Volume: 10 | Issue: 10 | Pages: 2606

10.3390/biomedicines10102606 | PMID 36289867 Get It

Peripheral nerve stimulation (PNS) has been utilized for over 50 years with accumulating evidence of efficacy in a variety of chronic pain conditions. The level and strength of evidence supporting the use of PNS for peripheral neuropathic pain remains unclear. The purpose of this review is to synthesize data from prospective studies on the efficacy of PNS for neuropathic pain as it pertains to pain intensity, neurological deficits/neuropathy (e.g., weakness, sensory deficits, gait/balance), and other secondary outcomes (quality of life, satisfaction, emotional functioning, and adverse events). In compliance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines, this review identified articles from MEDLINE(R), EMBASE, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and Scopus. Overall, per the Grading of Recommendations Assessment, Development and Evaluation (GRADE) criteria, pooled results demonstrate very low quality or low quality of evidence supporting modest to substantial improvement in pain and neurological function after PNS implantation for treatment of peripheral neuropathic pain. PNS for phantom limb pain was the only indication that had moderate level evidence. Future prospective and well-powered studies are warranted to assess the efficacy of PNS for peripheral neuropathic pain.
Cross-Ancestry Investigation of Venous Thromboembolism Genomic Predictors
Thibord, Florian , Klarin, Derek , Brody, Jennifer A. , Chen, Ming‐Huei , Levin, Michael G. , Chasman, Daniel I. , Goode, Ellen L. , Teder‐Laving, Maris , Martínez-Pérez, Ángel , Daian-Bacq, Delphine, Ito, Kaoru , Natarajan, Pradeep , Lutsey, Pamela L. , Nadkarni, Girish N. , Vries, Paul S. de , Wolford, Brooke N. , Pattee, Jack , Brækkan, Sigrid K. , Li‐Gao, Ruifang , Saut, Noémie , Sept, Corriene, Judy, Renae , O’Donnell, Christopher J. , Giulianini, Franco, Boland, Anne , Empana, Jean‐Philippe , Gilliland, Thomas , Do, Ron , Wang, Xin , Zhou, Wei , Soria, José Manuel , Souto, Juan Carlos , Haessler, Jeffery, Hindberg, Kristian , Bartz, Traci M. , Heckbert, Susan R. , Armasu, Sebastian M. , Brumpton, Ben , Smadja, David M. , Jouven, Xavier , Loos, Ruth J. F. , Sabater‐Lleal, Maria , Pankow, James S. , Reiner, Alex P. , Vlieg, Astrid van Hylckama , Deleuze, Jean-François, Skogholt, Anne Heidi , Emmerich, Joseph , Tang, Weihong , Jackson, Rebecca D. , Hansen, John‐Bjarne , Morange, Pierre‐Emmanuel , Kabrhel, Christopher , Johnson, Andrew D. , Smith, Nicholas L. , Martinez-Perez, Angel , Aïssi, Dylan , Ito, Kaoru , Natarajan, Pradeep , Lutsey, Pamela L , Nadkarni, Girish N , de Vries, Paul S , Wolford, Brooke N , Kooperberg, Charles , Braekkan, Sigrid K , Li-Gao, Ruifang , Saut, Noemie , Germain, Marine , Wiggins, Kerri L , Ko, Darae , O'Donnell, Christopher J , Taylor, Kent D , de Andrade, Mariza , Nøst, Therese H , Boland, Anne , Empana, Jean Philippe , Gilliland, Thomas , Do, Ron , Wang, Xin , Manuel Soria, Jose , Carlos Souto, Juan , Pankratz, Nathan , Rosendaal, Frits R , Turman, Constance , Olaso, Robert , Bartz, Traci M , Lynch, Julie A , Heckbert, Susan R , Brumpton, Ben , Smadja, David M , Komuro, Issei , Clapham, Katharine R , Loos, Ruth J F , Willer, Cristen J , Sabater-Lleal, Maria , Pankow, James S , Reiner, Alexander P , Ridker, Paul M. , Rader, Daniel J , Min Lee, Kyung , Psaty, Bruce M , Rich, Stephen S , Vy, Ha My T , Tang, Weihong , Damrauer, Scott M , Johnson, Andrew D , Smith, Nicholas L , Chasman, Daniel I , Brody, Jennifer A , Hveem, Kristian , Cuéllar-Partida, Gabriel , Kooperberg, Charles , Germain, Marine , Wiggins, Kerri L. , Taylor, Kent D. , Andrade, Mariza de , Koyama, Satoshi , Huffman, Jennifer E. , Pankratz, Nathan , Turman, Constance , Kember, Rachel L. , Lynch, Julie A. , Morelli, Vânia Maris , Deleuze, Jean‐François , Kraft, Peter , Lee, Kyung Min , Psaty, Bruce M. , Suchon, Pierre , Rich, Stephen S. , Trégouët, David‐Alexandre

Mayo Clinic

Circulation | October 17, 2022 | Volume: 146 | Issue: 16 | Pages: 1225-1242

10.1161/circulationaha.122.059675 | PMID 36154123 Get It

Background: Venous thromboembolism (VTE) is a life-threatening vascular event with environmental and genetic determinants. Recent VTE genome-wide association studies (GWAS) meta-analyses involved nearly 30 000 VTE cases and identified up to 40 genetic loci associated with VTE risk, including loci not previously suspected to play a role in hemostasis. The aim of our research was to expand discovery of new genetic loci associated with VTE by using cross-ancestry genomic resources. Methods: We present new cross-ancestry meta-analyzed GWAS results involving up to 81 669 VTE cases from 30 studies, with replication of novel loci in independent populations and loci characterization through in silico genomic interrogations. Results: In our genetic discovery effort that included 55 330 participants with VTE (47 822 European, 6320 African, and 1188 Hispanic ancestry), we identified 48 novel associations, of which 34 were replicated after correction for multiple testing. In our combined discovery-replication analysis (81 669 VTE participants) and ancestry-stratified meta-analyses (European, African, and Hispanic), we identified another 44 novel associations, which are new candidate VTE-associated loci requiring replication. In total, across all GWAS meta-analyses, we identified 135 independent genomic loci significantly associated with VTE risk. A genetic risk score of the significantly associated loci in Europeans identified a 6-fold increase in risk for those in the top 1% of scores compared with those with average scores. We also identified 31 novel transcript associations in transcriptome-wide association studies and 8 novel candidate genes with protein quantitative-trait locus Mendelian randomization analyses. In silico interrogations of hemostasis and hematology traits and a large phenome-wide association analysis of the 135 GWAS loci provided insights to biological pathways contributing to VTE, with some loci contributing to VTE through well-characterized coagulation pathways and others providing new data on the role of hematology traits, particularly platelet function. Many of the replicated loci are outside of known or currently hypothesized pathways to thrombosis. Conclusions: Our cross-ancestry GWAS meta-analyses identified new loci associated with VTE. These findings highlight new pathways to thrombosis and provide novel molecules that may be useful in the development of improved antithrombosis treatments.
Summary of the experiences, knowledge, medical management, and family communication of monoallelic MUTYH carriers
McKenna, Danielle , Sanchez, Pauleen, Powers, Jacquelyn , Brower, Jamie , Wang, Louise , Mueller, Rebecca , Symecko, Heather , Hamilton, Jada G. , Wildman, Temima , Offit, Kenneth , McKenna, Danielle B , Katona, Bryson W , Domchek, Susan M. , Couch, Fergus J. , Garber, Judy E. , Robson, Mark E.

Mayo Clinic

Journal of Genetic Counseling | October 17, 2022 | Volume: 32 | Issue: 2 | Pages: 342-350

10.1002/jgc4.1641 | PMID 36245263 Get It

AbstractGermline genetic testing for inherited cancer risk is increasingly being performed with multigene panel testing with MUTYH often included on colorectal cancer‐ and polyposis‐focused panels, as well as on broader pan‐cancer panels. With up to 1%–2% of the general population being monoallelic MUTYH carriers, pathogenic/likely pathogenic (P/LP) variants in MUTYH are one of the most common findings on multigene cancer panels. However, little is known about patient experience and understanding of monoallelic MUTYH P/LP variants, nor whether such findings influence medical management recommendations and familial communication, which this study aims to better understand. Monoallelic P/LP MUTYH carriers were recruited from the Prospective Registry of Multiplex Testing (PROMPT) and completed a cross‐sectional self‐report survey on sociodemographic characteristics, medical and family history, experiences with MUTYH genetic testing, genetics and MUTYH knowledge, perceived cancer risk, and familial communication. Of 115 eligible PROMPT participants, 49 (43%) completed the survey who were primarily female (94%), white (96%), had a history of cancer (61%), and a median age of 51.4 years. Most participants (61%) reported satisfaction with how their healthcare provider managed their genetic test result and care, and 65% of survey participants reported their provider recommended colonoscopy based on their genetic test results. Participants' responses also reflected variable levels of knowledge regarding cancer risks and screening recommendations for MUTYH carriers. The majority (98%) of participants shared their genetic test results with at least some of their relatives; however, only 13% of eligible relatives reportedly underwent cascade testing. Taken together, this study provides needed insight into the overall experiences of monoallelic MUTYH carriers and highlights numerous areas for improvement in clinician education, communication, and management of these individuals.
Characterization of Intercalated Cell Markers KIT and LINC01187 in Chromophobe Renal Cell Carcinoma and Other Renal Neoplasms
Mannan, Rahul , Zhang, Yuping , Chinnaiyan, Anya, Dagar, Aniket , Zelenka-Wang, Sylvia, McMurry, Lisa, Daniel, Nikita, Cao, Xuhong , Gupta, Sounak , Vaishampayan, Ulka N. , Hafez, Khaled S., Morgan, Todd M. , Spratt, Daniel E. , Tretiakova, Maria , Argani, Pedram , Mehra, Rohit , Skala, Stephanie L , Sangoi, Ankur R , Gupta, Sounak , Tretiakova, Maria S , Mehra, Rohit , Spratt, Daniel E , Morgan, Todd M , Vaishampayan, Ulka , Wang, Xiaoming , Bawa, Pushpinder , Skala, Stephanie L. , Wang, Lisha , Daniel, Nikita, Sangoi, Ankur R. , Chinnaiyan, Arul , Dhanasekaran, Saravana Mohan

Mayo Clinic

International Journal of Surgical Pathology | October 17, 2022 | Volume: 31 | Issue: 6 | Pages: 1027-1040

10.1177/10668969221125793 | PMID 36250542 Get It

Introduction. Chromophobe renal cell carcinoma (chromophobe RCC) is the third major subcategory of renal tumors after clear cell RCC and papillary RCC, accounting for approximately 5% of all RCC subtypes. Other oncocytic neoplasms seen commonly in surgical pathology practice include the eosinophilic variant of chromophobe RCC, renal oncocytoma, and low-grade oncocytic unclassified RCC. Methods. In our recent next-generation sequencing based study, we nominated a lineage-specific novel biomarker LINC01187 (long intergenic non-protein coding RNA 1187) which was found to be enriched in chromophobe RCC. Like KIT (cluster of differentiation 117; CD117), a clinically utilized chromophobe RCC related biomarker, LINC01187 is expressed in intercalated cells of the nephron. In this follow-up study, we performed KIT immunohistochemistry and LINC01187 RNA in situ hybridization (RNA-ISH) on a cohort of chromophobe RCC and other renal neoplasms, characterized the expression patterns, and quantified the expression signals of the two biomarkers in both primary and metastatic settings. Results. LINC01187, in comparison to KIT, exhibits stronger and more uniform expression within tumors while maintaining temporal and spatial consistency. LINC01187 also is devoid of intra-tumoral heterogeneous expression pattern, a phenomenon commonly noted with KIT. Conclusions. LINC01187 expression can augment the currently utilized KIT assay and help facilitate easy microscopic analyses in routine surgical pathology practice.
Danlou Tablet May Alleviate Vascular Injury Caused by Chronic Intermittent Hypoxia through Regulating FIH-1, HIF-1, and Angptl4
Rong, Yi , Wu, Qian , Tang, Jingjing , Liu, Zhiguo , Lv, Qianyu, Ye, Xuejiao , Dong, Yu , Zhang, Yuebo , Wang, Shihan , Li, Guangxi , Wang, Shihan , Li, Guangxi

Mayo Clinic

Evidence-Based Complementary and Alternative Medicine | October 15, 2022 | Volume: 2022 | Issue: No issue available | Pages: 1-13

10.1155/2022/4463108 | PMID 36285165 Get It

Background. Danlou tablet (DLT), the traditional Chinese medicine has been commonly used for dyslipidemia, atherosclerosis, and coronary heart disease. Whether it was effective against vascular injury caused by CIH has remained unknown. The aim of the current study was to observe the effects of DLT on chronic intermittent hypoxia (CIH)-induced vascular injury via regulation of blood lipids and to explore potential mechanisms. Methods. Sixteen 12-week-old male ApoE−/− mice were randomly divided into four groups. The sham group was exposed to normal room air, whereas the other three groups were exposed to CIH. Mice in the CIH + normal saline (NS) group were gavaged with NS. Mice in the CIH + Angptl4-ab group were intraperitoneally injected with Angptl4-antibody. Mice in the CIH + DLT group were gavaged with DLT. After four weeks of intervention, serum lipid concentrations, and serum lipoprotein lipase (LPL) activity were detected. The changes in atherosclerosis in vascular tissue were detected by hematoxylin and eosin (H&E) staining. Quantitative real-time polymerase chain reaction (qRT-PCR) and Western blot analysis were applied to detect the expression levels of hypoxia-induciblefactor-1 (HIF-1), factor-inhibiting HIF-1 (FIH-1), angiopoietin-like 4 (Angptl4), and LPL in different tissues. Results. CIH exposure increases serum lipid levels, decreases serum LPL activity, and exacerbates atherosclerosis. Both Angptl4-ab and DLT treatment reversed the changes in lipid concentration, LPL activity, and atherosclerosis caused by CIH. In the epididymal fat pad, CIH exposure decreased the expression of FIH-1 and increased the expression of HIF-1, whereas DLT treatment increased the expression of FIH-1 and LPL and inhibited the expression of HIF-1 and Angptl4. In heart tissue, the expression levels of LPL and Angptl4 were not affected by modeling or treatment. Conclusions. DLT improved vascular damage by improving the increase in blood lipids induced by CIH, potentially by upregulating FIH-1 and downregulating HIF-1 and Angptl4 in adipose tissue. Therefore, DLT may be a promising agent for the prevention and treatment of CIH-induced vascular injury.
NAV3 is a genetic determinant of myocardial recovery in dilated cardiomyopathy and attenuates cardiac fibrosis
Wang, M, Liu, D, Nguyen, T. T. , McNamara, Dennis M. , Barlera, Simona, Merlo, M, Krejci, J, Kilianova, A, Groote, P De, Weishilboum, R, Pereira, Naveen L. , Pileggi, Silvana , Mestroni, Luisa , Merlo, Marco , Sinagra, Gianfranco , Pinet, F , Groote, Pascal de

Mayo Clinic

European Heart Journal | October 15, 2022 | Volume: 43 | Issue: Supplement_2 | Pages: No page available

10.1093/eurheartj/ehac544.2990 Get It

Abstract Background A genome-wide association study (GWAS) assessing change in left ventricular ejection fraction (LVEF) in dilated cardiomyopathy (DCM), a surrogate marker of morbidity and mortality in heart failure (HF), had not been performed previously and could provide insight into novel biological pathways that could lead to the development of new drugs that might target myocardial recovery. The presence and extent of cardiac fibrosis in DCM is independently associated with myocardial recovery and cardiovascular mortality. Purpose To identify the biological relevance of genetic targets that are associated with change in LVEF in patients with DCM. Methods A GWAS was performed using DNA from 686 patients with recent onset DCM who were on standard HF therapy using change in LVEF at a median of 6 months after initial diagnosis. Cultured human cardiac fibroblasts (HCFs) were used as an in vitro model to study the functional and biological relevance of the gene target identified in the GWAS. Specifically, HCFs were transfected with siRNA by using the Lipofectamine™ RNAiMAX Transfection Reagent for gene knockdown (KD). RNA-seq was performed using the Illumina TruSeq protocol with expression analysis conducted with the EdgeR package. Ingenuity Pathway Analysis was used. Results A single-nucleotide polymorphism, rs11105445(G&gt;A), mapping to the neuron navigator 3 (NAV3) gene (rs11105445, p=2.37E-07; beta 2.74±0.53) was associated with improvement in LVEF. We performed a phenome-wide association study using data from the UK Biobank and demonstrated that genetic variation in NAV3 was significantly associated with HF mortality (p=3.2E-28), highlighting the potential importance of this gene in HF. Using GTEx data we demonstrated that in LV tissue the minor allele A was associated with ↓NAV3 expression (p=0.03) suggesting that ↓NAV3 expression might be associated with improvement in LVEF. We demonstrated that NAV3 KD significantly ↓TGF-β1 mediated HCF transdifferentiation into myofibroblasts, ↓α-smooth muscle actin (ACTA2) and ↓collagen I (COL1A1), therefore NAV3 KD was anti-fibrotic (see Figure 1), 1a. HCFs treated by vehicle/TGF-β1 after KD of NAV3/ctrl, and ACTA2 and COL1A1 were analyzed by qPCR; 1b. Representative immunofluorescence staining for α-SMA (in green), RNA-seq after NAV3 KD followed by pathway analysis suggested that NAV3 exerted its effect by regulating cell cycle related proteins (Figure 2), 2a. Volcano plot shows significant differentially expressed genes identified by RNA-seq analysis (down-regulated in blue, up-regulated in red); 2b. NAV3 KD significantly increased expression of cell cycle related proteins, which was validated by Western blot. Conclusions Decreased expression of NAV3 is associated with myocardial recovery in DCM, most likely due to its anti-fibrotic effect via direct regulation of cell cycle proteins. The role of NAV3 as a novel therapeutic target in DCM needs to be explored. Funding Acknowledgement Type of funding sources: Public Institution(s). Main funding source(s): Mayo Clinic Center for Individualized MedicineMayo Clinic Department of Cardiovascular Medicine